Small cell lung cancer: Will recent progress lead to improved outcomes?

M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, Charles M. Rudin

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiationsensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6% of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here.

Original languageEnglish (US)
Pages (from-to)2244-2255
Number of pages12
JournalClinical Cancer Research
Volume21
Issue number10
DOIs
StatePublished - May 15 2015

Fingerprint

Small Cell Lung Carcinoma
Neoplasm Metastasis
Therapeutics
Translational Medical Research
Etoposide
Platinum
Natural History
Research
Neoplasms
Survival Rate
Research Personnel
Drug Therapy
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Small cell lung cancer : Will recent progress lead to improved outcomes? / Pietanza, M. Catherine; Byers, Lauren Averett; Minna, John D.; Rudin, Charles M.

In: Clinical Cancer Research, Vol. 21, No. 10, 15.05.2015, p. 2244-2255.

Research output: Contribution to journalArticle

Pietanza, M. Catherine ; Byers, Lauren Averett ; Minna, John D. ; Rudin, Charles M. / Small cell lung cancer : Will recent progress lead to improved outcomes?. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 10. pp. 2244-2255.
@article{73d71e8767cf480db1b48341b4fab301,
title = "Small cell lung cancer: Will recent progress lead to improved outcomes?",
abstract = "Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiationsensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6{\%} of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here.",
author = "Pietanza, {M. Catherine} and Byers, {Lauren Averett} and Minna, {John D.} and Rudin, {Charles M.}",
year = "2015",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-14-2958",
language = "English (US)",
volume = "21",
pages = "2244--2255",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Small cell lung cancer

T2 - Will recent progress lead to improved outcomes?

AU - Pietanza, M. Catherine

AU - Byers, Lauren Averett

AU - Minna, John D.

AU - Rudin, Charles M.

PY - 2015/5/15

Y1 - 2015/5/15

N2 - Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiationsensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6% of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here.

AB - Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiationsensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6% of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here.

UR - http://www.scopus.com/inward/record.url?scp=84941986957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941986957&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-2958

DO - 10.1158/1078-0432.CCR-14-2958

M3 - Article

C2 - 25979931

AN - SCOPUS:84941986957

VL - 21

SP - 2244

EP - 2255

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -